| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
| Targets |
BODIPY-Cholesterol does not target a specific protein or enzyme. Instead, it functions as a fluorescent cholesterol analog that incorporates into cellular membranes and mimics the behavior of natural cholesterol. The compound can be used to monitor sterol uptake and sterol flux between organelles. Its interaction with membranes is based on its lipophilic properties and structural similarity to cholesterol, allowing it to partition into lipid bilayers and associate with cholesterol-binding proteins.
|
|---|---|
| ln Vitro |
BODIPY-cholesterol assay: The analogue is reconstituted in DMSO to a stock concentration of 1–10 μM in order to provide a stock solution for this assay[1]. PBS (or other buffer)-diluted cells are rinsed (300× g, 10 min) to eliminate surplus diluent, and the loose pellet is then resuspended in vehicle media at the appropriate concentration[1]. BODIPY-cholesterol (final concentration of 0.5–5 μM) is added to cell suspensions, combined well, and incubated at 37 °C for 10–20 minutes[1]. Before being subjected to a flow cytometric examination, the cells are incubated for two hours after being diluted with each of the capacitation medium conditions as described in Incubation media to a final concentration[1].
The in vitro activity of BODIPY-Cholesterol is its function as a fluorescent probe for studying cholesterol dynamics. The compound mimics natural cholesterol in membrane incorporation and transport behavior. It can be used to monitor sterol uptake and sterol flux between organelles in live cells. The BODIPY fluorophore provides strong, photostable fluorescence, enabling the tracking of cholesterol in cellular membranes, lipoproteins, and organelles involved in lipid homeostasis. |
| ln Vivo |
BODIPY-Cholesterol is not used as a therapeutic agent. Its in vivo utility is limited to research applications involving the study of cholesterol trafficking and lipid metabolism. The compound is not intended for systemic therapeutic use.
|
| Enzyme Assay |
In vitro assays for BODIPY-Cholesterol involve incubating cells with the fluorescent cholesterol analog. The compound is taken up by cells and incorporated into membranes, mimicking natural cholesterol behavior. The fluorescence can be detected by fluorescence microscopy or flow cytometry to study cholesterol distribution, trafficking, and dynamics in cells.
|
| Cell Assay |
For in vitro cellular experiments, BODIPY-Cholesterol is dissolved in appropriate solvents and added to cell culture medium. Cells are incubated with the compound for a defined period, washed, and then analyzed by fluorescence microscopy. The fluorescent cholesterol analog allows for the visualization of sterol movement and lipid domains in live cells. It can be used to study cholesterol uptake, intracellular transport, and organelle distribution.
|
| Animal Protocol |
For in vivo animal experiments, BODIPY-Cholesterol can be used to study cholesterol metabolism and trafficking. The compound can be administered to animal models, and its distribution can be tracked by fluorescence imaging. However, such studies are not commonly reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of BODIPY-Cholesterol have not been extensively characterized, as the compound is a research-use fluorescent probe rather than a drug candidate. The compound has a molecular weight of 576.61 g/mol and should be stored at -20°C, protected from light.
|
| Toxicity/Toxicokinetics |
BODIPY-Cholesterol is intended for research use only and not for human therapeutic or diagnostic applications. Standard laboratory safety precautions should be observed when handling this chemical reagent.
|
| References | |
| Additional Infomation |
BODIPY-Cholesterol (CAS#: 878557-19-8) is a fluorescent cholesterol analog that allows visualization of sterol movement and lipid domains. It mimics natural cholesterol in membrane incorporation and transport behavior and is used to monitor sterol uptake and sterol flux between organelles. The compound has no clinical or therapeutic applications.
|
| Molecular Formula |
C36H51BF2N2O
|
|---|---|
| Molecular Weight |
576.61
|
| Exact Mass |
576.406
|
| CAS # |
878557-19-8
|
| PubChem CID |
11642697
|
| Appearance |
Yellow to orange solid powder
|
| LogP |
8.162
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
42
|
| Complexity |
1240
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
[B-]1(N2C(=CC(=C2C(=C3[N+]1=C(C=C3C)C)CC[C@@H](C)[C@H]4CC[C@@H]5[C@@]4(CC[C@H]6[C@H]5CC=C7[C@@]6(CC[C@@H](C7)O)C)C)C)C)(F)F
|
| InChi Key |
CFFWELDLDWZNRO-ZVEUZXBYSA-N
|
| InChi Code |
InChI=1S/C36H51BF2N2O/c1-21(8-10-29-33-22(2)18-24(4)40(33)37(38,39)41-25(5)19-23(3)34(29)41)30-12-13-31-28-11-9-26-20-27(42)14-16-35(26,6)32(28)15-17-36(30,31)7/h9,18-19,21,27-28,30-32,42H,8,10-17,20H2,1-7H3/t21-,27+,28+,30-,31+,32+,35+,36-/m1/s1
|
| Chemical Name |
(3S,8S,9S,10R,13R,14S,17R)-17-[(2R)-4-(2,2-difluoro-4,6,10,12-tetramethyl-3-aza-1-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-1(12),4,6,8,10-pentaen-8-yl)butan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 1 mg/mL (1.73 mM)
H2O: < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7343 mL | 8.6714 mL | 17.3427 mL | |
| 5 mM | 0.3469 mL | 1.7343 mL | 3.4685 mL | |
| 10 mM | 0.1734 mL | 0.8671 mL | 1.7343 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
